SEI Investments’s Intellia Therapeutics NTLA Stock Holding History

SEI Investments’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Sell	17,790 -2,303	-11%	-$32.2K	﹤0.01%	2865
2026 Q1	$258K	Buy	20,093 +2,316	+13%	+$29.5K	﹤0.01%	2876
2025 Q4	$160K	Sell	17,777 -16,974	-49%	-$234K	﹤0.01%	2949
2025 Q3	$600K	Buy	34,751 +8,476	+32%	+$104K	﹤0.01%	2155
2025 Q2	$247K	Buy	26,275 +9,739	+59%	+$80K	﹤0.01%	2485
2025 Q1	$118K	Buy	+16,536	New	+$167K	﹤0.01%	2572
2024 Q4	–	Sell	-19,844	Closed	-$408K	–	2769
2024 Q3	$408K	Buy	19,844 +10,562	+114%	+$244K	﹤0.01%	2247
2024 Q2	$208K	Buy	9,282 +1,837	+25%	+$43.7K	﹤0.01%	2447
2024 Q1	$205K	Buy	7,445 +470	+7%	+$13.1K	﹤0.01%	2421
2023 Q4	$213K	Sell	6,975 -1,220	-15%	-$35.1K	﹤0.01%	2425
2023 Q3	$259K	Buy	8,195 +506	+7%	+$19.6K	﹤0.01%	2353
2023 Q2	$314K	Buy	+7,689	New	+$312K	﹤0.01%	2321
2022 Q4	–	Sell	-9,236	Closed	-$517K	–	2634
2022 Q3	$517K	Buy	9,236 +2,511	+37%	+$156K	﹤0.01%	2071
2022 Q2	$348K	Buy	+6,725	New	+$341K	﹤0.01%	2259
2022 Q1	–	Sell	-3,565	Closed	-$422K	–	2626
2021 Q4	$422K	Sell	3,565 -9,905	-74%	-$1.24M	﹤0.01%	2198
2021 Q3	$1.81M	Sell	13,470 -621	-4%	-$94K	﹤0.01%	1546
2021 Q2	$2.28M	Buy	+14,091	New	+$1.1M	0.01%	1461
2018 Q4	–	Sell	-4,745	Closed	-$80K	–	2661
2018 Q3	$80K	Sell	4,745 -1,121	-19%	-$32.6K	﹤0.01%	2131
2018 Q2	$160K	Buy	5,866 +5,066	+633%	+$123K	﹤0.01%	2132
2018 Q1	$17K	Buy	+800	New	+$19.7K	﹤0.01%	2699

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

SEI Investments's NTLA Position: Q2 2026 in Review

SEI Investments reduced its Intellia Therapeutics (NTLA) stake by 11% in Q2 2026, selling an estimated $32.2K and leaving 17,790 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #2865.

SEI Investments first reported a position in NTLA in Q1 2018 and has held it in 20 quarters since. The position peaked at $2.28M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

SEI Investments held 17,790 shares of Intellia Therapeutics worth $301K as of Q2 2026.
SEI Investments sold 2,303 Intellia Therapeutics shares in Q2 2026, an estimated $32.2K.
Intellia Therapeutics made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #2865 holding.
SEI Investments first reported a position in Intellia Therapeutics in Q1 2018 and has held it in 20 quarters since.
SEI Investments's Intellia Therapeutics position peaked at $2.28M in Q2 2021.
328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.